<p>The value in the different drug columns indicates the average Log FC in the presence of this mutation, when not available in the dataset the value is denoted ‘n/a’. Mutations indicated with an asterisk were incompletely tested on all drugs in the dataset. Like the NNRTI resistance mutations, each mutation displays a different resistance profile over all drugs. AZT is seen to be the most susceptible (average Log FC 0.69) and TDF the least susceptible (average Log FC 0.27).</p
<p>n: number of resistance tests (first test/patient per year) presenting with mutations associated ...
*<p>Significant <i>p</i>-values at the 0.05 level are boldfaced</p>**<p>NA, data not available</p
<p>Nucleoside/tide Reverse Transcriptase Inhibitor (NRTI) mutation profiles associated with failure ...
<p>The value in the different drug columns indicates the average Log FC in the presence of this muta...
<p>NNRTI: non nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase in...
<p>The pattern produced by our model correlates with literature. <a href="http://www.ploscompbiol.or...
<p>In vitro susceptibilities associated with the 9 NNRTI drug resistance mutation patterns.</p
<p>DRM: Drug resistance mutations; NRTI: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; NNR...
<p>Drug resistance mutation frequency is shown for the studies included in the meta-analysis. Only s...
<p>HIV-1 drug resistance genotyping analyses of the <i>pol</i> region were performed for all the DBS...
<p>Drug resistance mutation frequency is shown for the studies included in the meta-analysis. Only s...
Determining the phenotypic impacts of reverse transcriptase (RT) mutations on individual nucleoside ...
<p>Footnote: *No.: Number of patients receiving first-line therapy with the ARV regimen indicated in...
<p>Percentage of sequences having resistance mutations to NRTI (red), NNRTI (yellow), PI (green), an...
<p>250 samples from 234 drug-naive patients and 115 samples from 78 treated A/AE patients were genot...
<p>n: number of resistance tests (first test/patient per year) presenting with mutations associated ...
*<p>Significant <i>p</i>-values at the 0.05 level are boldfaced</p>**<p>NA, data not available</p
<p>Nucleoside/tide Reverse Transcriptase Inhibitor (NRTI) mutation profiles associated with failure ...
<p>The value in the different drug columns indicates the average Log FC in the presence of this muta...
<p>NNRTI: non nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase in...
<p>The pattern produced by our model correlates with literature. <a href="http://www.ploscompbiol.or...
<p>In vitro susceptibilities associated with the 9 NNRTI drug resistance mutation patterns.</p
<p>DRM: Drug resistance mutations; NRTI: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; NNR...
<p>Drug resistance mutation frequency is shown for the studies included in the meta-analysis. Only s...
<p>HIV-1 drug resistance genotyping analyses of the <i>pol</i> region were performed for all the DBS...
<p>Drug resistance mutation frequency is shown for the studies included in the meta-analysis. Only s...
Determining the phenotypic impacts of reverse transcriptase (RT) mutations on individual nucleoside ...
<p>Footnote: *No.: Number of patients receiving first-line therapy with the ARV regimen indicated in...
<p>Percentage of sequences having resistance mutations to NRTI (red), NNRTI (yellow), PI (green), an...
<p>250 samples from 234 drug-naive patients and 115 samples from 78 treated A/AE patients were genot...
<p>n: number of resistance tests (first test/patient per year) presenting with mutations associated ...
*<p>Significant <i>p</i>-values at the 0.05 level are boldfaced</p>**<p>NA, data not available</p
<p>Nucleoside/tide Reverse Transcriptase Inhibitor (NRTI) mutation profiles associated with failure ...